The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

This has been linked to lifestyle changes, metabolic diseases, and obesity, with cases increasingly being reported in women ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve outcomes versus chemotherapy.